NumberOfSamples: 65 colorectal cancer (CRC) cell lines  
NumberOfSamples: 90 CRC patients  
NumberOfSamples: 1,074 CRC tumours  
AssayName: mass spectrometry  
AssayName: immunohistochemistry  
CellLine: SW480  
NumberOfSamples: 1,074 patients from the QUASAR 2 clinical trial cohort  
Experiment: QUASAR 2  
TumorStage: stage II/III CRC patients  
Temperature: 37°C  
SampleTreatment: RIPA100 buffer (20 mM Tris–HCl pH 7.5, 1 mM EDTA, 100 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate and 0.1% SDS) containing protease (Complete™ mini with EDTA; Roche) and phosphatase inhibitors (Phosphatase Inhibitor cocktail 1 and 2; Sigma Aldrich) at 2× and 5× the final concentration recommended by the manufacturer  
SamplingTime: 30 min at 4°C  
ReductionReagent: 10 mM DTT  
AlkylationReagent: 55 mM chloroacetamide  
CleavageAgent: trypsin (Roche)  
SampleTreatment: acetone-precipitated overnight using four volumes of pre-cooled (−40°C) acetone  
Temperature: −40°C  
FractionationMethod: hydrophilic strong anion exchange (hSAX) chromatography  
Temperature: 30°C  
FlowRateChromatogram: 250 μl/min  
AcquisitionMethod: nanoflow LC-MS/MS  
Instrument: Orbitrap Velos mass spectrometer  
FlowRateChromatogram: 300 nl/min  
FragmentationMethod: higher-energy collisional dissociation (HCD)  
AcquisitionMethod: data-dependent acquisition  
Instrument: Orbitrap Elite mass spectrometer  
CleavageAgent: Trypsin/P